Viral Clearance Patents: Who Leads, Where the Gaps Are 2026
- 70.5% concentrated at the top. The top 5 of 34 ranked assignees combined account for 93 of the 132 records in scope — a field where a handful of filers set the terms.
- Filing activity peaked in 2017 at 14 records. and has run flat-to-declining since, with the 2022 midpoint at just 2 — a sign that claim space around the core routes may already be staked out.
- C07K peptide/protein claims dominate at 55.3%. while separation processes (B01D, 33.3%) and bioreactor apparatus (C12M, 29.5%) trail well behind — showing where the crowding really sits.
What this landscape covers
Viral clearance and inactivation patents span the methods and equipment used to remove or destroy viral contaminants during biologic drug manufacture — low pH inactivation, virus filtration membranes, chromatography-based clearance, and the validation protocols regulators require before a process is approved. This landscape draws on 132 published records filed between 2015 and mid-2026, indexed under IPC classes covering separation processes, peptide and protein purification, sterilisation, and microorganism handling.
The record set is concentrated: a small group of assignees holds most of the filings, and the technology composition skews heavily toward protein purification claims rather than the filtration hardware or bioreactor apparatus that support them. Because publication lags filing by roughly 18 months, the most recent year of activity always understates true filing volume.
Filing trends and technology composition
Two views of the same 132-record dataset: how filing activity has moved year over year, and how those records distribute across the IPC subclasses that define the technical routes to viral clearance.
Filing trend: a 2017 peak, then a flat tail
Filings ran at 14 records in 2017, the peak year so far, then declined toward a midpoint of 2 records in 2022. The most recent year is partial and will rise as later filings publish, but the multi-year trend line is flat to declining rather than accelerating.
Technology composition across 8 IPC subclasses
C07K (peptides and proteins) appears in 55.3% of the 132 records, ahead of A61L sterilising and disinfecting methods at 40.9% and C12N microorganism and genetic engineering claims at 34.1%. Because a single record can carry several IPC codes, these shares sum to well over 100% and should be read as overlap, not as a partition of the field.
Shares are the percentage of the 132 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Viral Clearance and Inactivation with Eureka
This page is one run against one query. Ask Eureka your own question about viral clearance and inactivation and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited records
EP3141611A2 — Validation method for continuous viral clearance
Disclosed herein is a method for validation of continuous viral clearance comprising providing a probe to be validated, spiking the probe in a valid manner, performing viral clearance, sampling the spiked probe and analyzing the sample.Filed by Bayer Healthcare, published 2017-03-15. The claim scope centres on the validation protocol itself — spiking, sampling and analysis steps — rather than a specific inactivation or filtration mechanism.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20150298070A1 | Ultraporous Nanofiber Mats And Uses Thereof | 31 |
| 2 | WO2011081898A1 | Membranes and associated methods for purification of antibodies | 29 |
| 3 | WO2018237159A1 | Cation exchange chromatography wash buffer | 17 |
| 4 | WO2020076681A1 | A novel continuous flow reactor for low PH viral inactivation | 16 |
| 5 | WO2013192009A1 | Virus filtration of cell culture media | 15 |
| 6 | US20160272676A1 | Protein Separations Using An Acrylamide Containing Filter | 13 |
| 7 | WO2015088677A1 | Protein separations using an acrylamide containing filter | 12 |
| 8 | US20110034674A1 | Virus filtration methods | 10 |
| 9 | WO2018075716A1 | Validation of continuous viral clearance | 9 |
| 10 | US20170260498A1 | Virus filtration of cell culture media | 7 |
Citation counts reward older filings that have had more time to accumulate citers inside this searched corpus — read them as a signal of influence on the field, not as a measure of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three figures from this dataset carry direct implications for where a new filing is likely to clear examination and where it will run straight into occupied claim space.
A small group sets the terms
The top 5 of 34 ranked assignees combined hold 93 of the 132 records in scope. New entrants filing on the core low pH inactivation or virus filtration routes are filing into space these five companies have already mapped extensively.
Flat-to-declining filing activity
Filing peaked at 14 records in 2017 and has not returned to that level since; the 2022 midpoint sat at just 2 records. Publication lag means the final year understates true volume, but the multi-year direction is clearly not accelerating.
Protein purification claims dominate
C07K peptide and protein claims appear in over half of all records, well ahead of separation processes (B01D, 33.3%) or bioreactor apparatus (C12M, 29.5%). Hardware and apparatus claims trail the molecule-level purification claims by a wide margin.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to viral clearance and inactivation, with the prior art for and against each one.
Who holds the claim space
The ranking covers 34 companies with published filings in scope. Filing concentration and co-assignee pairs both point to a field shaped by a small number of large biologics manufacturers and their corporate affiliates rather than a broad base of independent filers.
The single largest filer
The leading assignee holds 29 of the 132 records in scope, well ahead of the fifth-placed company at 12 — a gap that widens further once the tenth-placed company's 5 records are considered.
Corporate affiliates file jointly
Ten co-assignee pairs appear in the dataset, with the strongest pairing linked at 19 shared records — consistent with parent-subsidiary filing patterns rather than arm's-length collaboration between competitors.
Leaders have gone quiet recently
Several of the most active historical filers show zero filings in the latest year of the dataset. That is consistent with the broader flat-to-declining trend rather than a shift away from any single company.
| Assignee | Recent year | YoY |
|---|---|---|
| EMD Millipore Corp | 0 | — |
| Baxalta Inc | 0 | — |
| Baxalta GmbH | 0 | — |
| Takeda Pharmaceutical Co Ltd | 0 | — |
| Cephalon Inc | 0 | — |
| Baxter International Inc | 0 | — |
| Baxter Healthcare Corp | 0 | — |
| Bayer AG | 0 | — |
Where to take this analysis
This landscape identifies where filing activity concentrates and where it thins out. Turning that into a filing or freedom-to-operate decision means going deeper on the specific claims that matter to your own process.
Map claims against your own process route
Concentration at the top five assignees does not mean every claim blocks every process variant — the specific claim language around spiking, sampling and log reduction validation steps is what matters for freedom-to-operate.
Explore claim-level analysis in EurekaTrack the under-claimed branches
Continuous-flow inactivation and prion-specific validation show thinner filing density than the core low pH and filtration routes — worth monitoring before a competitor stakes out the claim space.
Set up monitoring in EurekaFrequently asked questions
Filing in this space is concentrated: the leading assignee holds 29 of the 132 records in scope, and the top 5 of 34 ranked companies combined account for 70.5% of all records. The gap between the leader and the rest of the field is substantial, with the fifth-placed company holding 12 records and the tenth-placed company holding 5. This concentration reflects the fact that large biologics manufacturers and their affiliates have been filing on core low pH inactivation and virus filtration methods for over a decade.
The trend is flat to declining. Filing peaked at 14 records in 2017 and had fallen to a midpoint of just 2 records by 2022. Because publication typically lags filing by around 18 months, the most recent year in the dataset understates true activity, but the multi-year trajectory does not show acceleration. This suggests the core technical routes may already be well mapped by existing filings rather than an area still opening up.
The dataset spans eight IPC subclasses, led by C07K (peptides and proteins) at 55.3% of the 132 records, A61L (sterilising and disinfecting) at 40.9%, and C12N (microorganisms and genetic engineering) at 34.1%. B01D, covering separation processes including filtration, appears in 33.3% of records. Because a single filing can carry multiple IPC codes, these percentages overlap rather than sum to 100%, reflecting how a single patent often combines a purification method with an apparatus or validation claim.
EP3141611A2, filed by Bayer Healthcare and published in 2017, claims a validation method for continuous viral clearance — specifically the steps of providing a probe, spiking it, performing viral clearance, sampling, and analyzing the sample. It is one of the representative filings in this dataset but its scope is centred on the validation protocol itself rather than a specific inactivation chemistry or filtration membrane design. Anyone filing on continuous viral clearance validation workflows should review its claim language closely, but it does not by itself block filings on different inactivation mechanisms.
The IPC composition points to apparatus and process-support classes as comparatively thin relative to the dominant protein purification claims: C08F addition polymer claims sit at 16.7% of records and C12Q enzyme/DNA testing claims at 12.9%, both well behind the leading classes. Sub-areas such as continuous-flow low pH inactivation reactors, orthogonal clearance for gene therapy vectors, and prion-specific validation protocols show thinner filing density than the core routes. These are worth investigating further before assuming the field is fully occupied.
Research Viral Clearance and Inactivation in depth with Eureka
Go past this page: query the whole viral clearance and inactivation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.